Evidence map›Paper›PMID 25884842›Full record

ArticleBMC cancer2015

In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors.

Federica Barbieri, Stefano Thellung, Alessandra Ratto, Elisa Carra, Valeria Marini, Carmen Fucile, Adriana Bajetto, Alessandra Pattarozzi, Roberto Würth, Monica Gatti and 7 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 57 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Metabolic Alterations in Canine Mammary Tumors.Animals : an open access journal from MDPI · 2023
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Federica BarbieriDipartimento di Medicina Interna, Sezione di Farmacologia, University of Genova, Genoa, Italy. federica.barbieri@unige.it.
Stefano ThellungDipartimento di Medicina Interna, Sezione di Farmacologia, University of Genova, Genoa, Italy. stefano.thellung@unige.it.
Alessandra RattoIstituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle D'Aosta, and National Reference Center of Veterinary and Comparative Oncology (CEROVEC), Genoa, Italy. alessandra.ratto@izsto.it.
Elisa CarraDipartimento di Medicina Sperimentale, University of Genova, Genoa, Italy. elisacarra@hotmail.it.
Valeria MariniDipartimento di Medicina Interna, Sezione di Farmacologia, University of Genova, Genoa, Italy. valeria.marini@unige.it.
Carmen FucileDipartimento di Medicina Interna, Sezione di Farmacologia, University of Genova, Genoa, Italy. antidpx@gmail.com.
Adriana BajettoDipartimento di Medicina Interna, Sezione di Farmacologia, University of Genova, Genoa, Italy. adriana.bajetto@unige.it.
Alessandra PattarozziDipartimento di Medicina Interna, Sezione di Farmacologia, University of Genova, Genoa, Italy. alpat25@hotmail.com.
Roberto WürthDipartimento di Medicina Interna, Sezione di Farmacologia, University of Genova, Genoa, Italy. roberto.wurth@unige.it.
Monica GattiDipartimento di Medicina Interna, Sezione di Farmacologia, University of Genova, Genoa, Italy. monica.gatti@unige.it.
Chiara CampanellaIstituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle D'Aosta, and National Reference Center of Veterinary and Comparative Oncology (CEROVEC), Genoa, Italy. chiara.campanella@izsto.it.
Guendalina VitoIstituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle D'Aosta, and National Reference Center of Veterinary and Comparative Oncology (CEROVEC), Genoa, Italy. guendalina.vito@izsto.it.
Francesca MattioliDipartimento di Medicina Interna, Sezione di Farmacologia, University of Genova, Genoa, Italy. fmattiol@unige.it.
Aldo PaganoDipartimento di Medicina Sperimentale, University of Genova, Genoa, Italy. aldo.pagano@unige.it.
Antonio DagaIRCCS AOU San Martino - IST, Genoa, Italy. antonio.daga@hsanmartino.it.
Angelo FerrariIstituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle D'Aosta, and National Reference Center of Veterinary and Comparative Oncology (CEROVEC), Genoa, Italy. angelo.ferrari@izsto.it.
Tullio FlorioDipartimento di Medicina Interna, Sezione di Farmacologia, University of Genova, Genoa, Italy. tullio.florio@unige.it.
University of Genoa · ITIstituto Zooprofilattico Sperimentale del Piemonte Liguria e Valle d'Aosta · ITOspedale Policlinico San Martino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer stem cells (CSCs) are considered the cell subpopulation responsible for breast cancer (BC) initiation, growth, and relapse. CSCs are identified as self-renewing and tumor-initiating cells, conferring resistance to chemo- and radio-therapy to several neoplasias. Nowadays, th (about 10mM)e pharmacological targeting of CSCs is considered an ineludible therapeutic goal. The antidiabetic drug metformin was reported to suppress in vitro and in vivo CSC survival in different tumors and, in particular, in BC preclinical models. However, few studies are available on primary CSC cultures derived from human postsurgical BC samples, likely because of the limited amount of tissue available after surgery. In this context, comparative oncology is acquiring a relevant role in cancer research, allowing the analysis of larger samples from spontaneous pet tumors that represent optimal models for human cancer.

methodsIsolation of primary canine mammary carcinoma (CMC) cells and enrichment in stem-like cell was carried out from fresh tumor specimens by culturing cells in stem-permissive conditions. Phenotypic and functional characterization of CMC-derived stem cells was performed in vitro, by assessment of self-renewal, long-lasting proliferation, marker expression, and drug sensitivity, and in vivo, by tumorigenicity experiments. Corresponding cultures of differentiated CMC cells were used as internal reference. Metformin efficacy on CMC stem cell viability was analyzed both in vitro and in vivo.

resultsWe identified a subpopulation of CMC cells showing human breast CSC features, including expression of specific markers (i.e. CD44, CXCR4), growth as mammospheres, and tumor-initiation in mice. These cells show resistance to doxorubicin but were highly sensitive to metformin in vitro. Finally, in vivo metformin administration significantly impaired CMC growth in NOD-SCID mice, associated with a significant depletion of CSCs.

conclusionsSimilarly to the human counterpart, CMCs contain stem-like subpopulations representing, in a comparative oncology context, a valuable translational model for human BC, and, in particular, to predict the efficacy of antitumor drugs. Moreover, metformin represents a potential CSC-selective drug for BC, as effective (neo-)adjuvant therapy to eradicate CSC in mammary carcinomas of humans and animals.

Indexed as

Mammary Neoplasms, AnimalAnimalsAntineoplastic AgentsBreast NeoplasmsCell Line, TumorCell ProliferationCell SurvivalDisease Models, AnimalDogsDrug Resistance, NeoplasmErbB ReceptorsEstrogen Receptor alphaFemaleHumansHyaluronan ReceptorsKi-67 AntigenAntineoplastic AgentsErbB ReceptorsEstrogen Receptor alphaHyaluronan ReceptorsKi-67 AntigenMetformin

Identifiers

PMID25884842
PMCPMC4397725
OpenAlexW2086213879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.